Bupropion (Zyban) is contraindicated for the treatment of smoking cessation in patients with:

Rationale: A. Hypothyroidism is not a contraindication for the use of bupropion in smoking cessation therapy. While bupropion can affect metabolic rate slightly through its noradrenergic effects, it does not interfere with thyroid hormone replacement or thyroid gland function. Patients with managed thyroid conditions can safely use this medication provided they do not have other neurological or psychiatric exclusions. B. Bupropion is actually an antidepressant medication, and its use is not contraindicated in patients with depression. In many cases, it may be a beneficial choice for smokers with co-occurring depressive symptoms as it targets both conditions simultaneously. However, all patients should be monitored for changes in mood or suicidal ideation, but a diagnosis of depression itself does not preclude its use. C. Bupropion significantly lowers the seizure threshold in a dose-dependent manner, making it strictly contraindicated in patients with a history of seizure disorders or epilepsy. Using this medication in such patients dramatically increases the risk of inducing a tonic-clonic seizure. This contraindication also extends to patients with conditions that predispose them to seizures, such as active eating disorders like anorexia or bulimia. D. There is no known contraindication for using bupropion in patients diagnosed with asthma. Unlike certain beta-blockers that might cause bronchoconstriction, bupropion does not interact with the respiratory system or interfere with standard asthma medications. It remains a safe and effective option for smoking cessation in patients with chronic obstructive or reactive airway diseases, provided their seizure history is clear.